---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-243431"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:03:29.342111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day

## Summary
- RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).
- For 2L+ PDAC patients (n=40) at 1,200 mg/day, ORR 30% (confirmed + pending), DCR 80%.
- Most common any-grade TRAEs at 1,200 mg/day: nausea (27%), diarrhea (20%), vomiting (15%), rash (10%).
- Median treatment duration 2.8 months across all doses; data cutoff September 2, 2024.

## SEC filing metadata
- accession: 0001193125-24-243431
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/0001193125-24-243431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/d890891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-243431
- JSON: https://secwatch.observer/filing/0001193125-24-243431.json
- Plain text: https://secwatch.observer/filing/0001193125-24-243431.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.